Turn Therapeutics Q2 2026: $5.85M Net Loss, Going Concern Warning, Cash Runway to Q3 2027
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics filed its Q2 2026 10-Q, reporting a $5.85 million net loss and $10.3 million in cash, with management raising substantial doubt about its ability to continue as a going concern. The filing details a $6.1 million derivative liability and the terms of its $25 million debt facility.
Key Events · Earnings and Guidance · TTRX
-
Going Concern Warning
Management states substantial doubt about the company's ability to continue as a going concern, with cash runway estimated only into Q3 2027.
-
Q2 Net Loss of $5.85M
Net loss for Q2 2026 was $5.85 million, up from $1.24 million in Q2 2025, driven by a $3.34 million non-cash loss from derivative liability remeasurement.
-
Derivative Liability Surge
Derivative liability instrument increased to $6.1 million from $3.0 million at year-end, primarily due to a $2.7 million increase in warrant fair value as the stock price rose.
-
Avenue Capital Loan Terms
The $25 million loan facility includes a $7 million Tranche 1 funded, with a conversion option allowing the lender to convert up to $2 million of principal at 80% of trading price.
Analysis · TTRX · Life Sciences
The 10-Q confirms the Q2 net loss of $5.85 million and cash of $10.3 million, but adds critical detail: management states substantial doubt about the company's ability to continue as a going concern, with cash runway only into Q3 2027. The derivative liability jumped to $6.1 million from $3.0 million, driven by a non-cash warrant remeasurement as the stock price rose. The company also disclosed the terms of its $25 million Avenue Capital loan, including a conversion option at 80% of trading price, and expanded its Phase 2 trial for GX-03. This is a material update for investors assessing the company's survival and dilution risk.
At the time of this filing, TTRX was trading at $10.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $314M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.